- ZEJULA® was the most prescribed PARP inhibitor in U.S. with Q3 net sales of
- Positive CHMP opinion issued for ZEJULA in E.U.; commercial launch anticipated to begin by year-end
- Expansion of niraparib development program underway for multiple tumor types
- VARUBI® IV approved by U.S.
FDA; commercial launch planned for November
- Phase 1 combination study of TSR-022 (anti-TIM-3) and TSR-042 (anti-PD-1) now enrolling patients
- Phase 1 study of TSR-033 (anti-LAG-3) now enrolling patients
“Exiting the third quarter, ZEJULA achieved 60% market share of the ovarian cancer patient population treated with a PARP inhibitor. This is a result of our team’s solid execution, and is supported by the feedback from physicians and patients, which continues to be excellent with regards to the benefit ZEJULA provides for women living with ovarian cancer,” said
Recent Business Highlights
October 25, 2017, the U.S. Food and Drug Administration( FDA) approved the intravenous (IV) formulation of VARUBI® (rolapitant), and the U.S. commercial launch is planned for November. The unit demand for VARUBI oral capsules increased 74% for Q3 2017 vs. Q3 2016, as the brand continues to penetrate the U.S. oral NK-1 market.
- ZEJULA® (niraparib) is the most prescribed PARP inhibitor in the U.S., with approximately 2,500 patients treated during the month of September.
- The European Medicines Agency’s (EMA)
Committee for Medicinal Products for Human Use(CHMP) issued a positive opinion for ZEJULA as a monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete response (CR) or partial response (PR) to platinum-based chemotherapy.
- Pre-launch preparations continue in support of a European launch of ZEJULA by year-end 2017 beginning with
Germany, pending European Commissionapproval.
- The niraparib expanded access program (EAP) in
Europehas enrolled more than 350 patients to date.
- Clinical trials were initiated to support planned Phase 3 studies of niraparib combined with our anti-PD-1 antibody, TSR-042, in patients with lung and ovarian cancers and to evaluate niraparib plus TSR-042 in patients with advanced or metastatic cancers suitable for treatment with an anti-PD-1 antibody, including ovarian and lung.
- Enrollment continues in the PRIMA trial of niraparib for patients with first-line ovarian cancer and the QUADRA trial of niraparib for the treatment of patients with ovarian cancer who have received three or more prior lines of chemotherapy.
- The Phase 2 TOPACIO trial of niraparib plus pembrolizumab is ongoing with additional data expected in 1H 2018. Preliminary Phase 2 data presented at ESMO showed activity in patients with platinum-resistant ovarian cancer and patients with triple-negative breast cancer.
- The Janssen GALAHAD Phase 2 efficacy and safety study of niraparib in men with metastatic castration-resistant prostate cancer and DNA-repair anomalies is ongoing to support a planned regulatory submission in 2019.
- Phase 1 data for TSR-042 (anti-PD-1 antibody) presented at ESMO demonstrated a predictable safety profile and clinical activity in heavily pre-treated patients. The GARNET registration trial of TSR-042 continues to enroll patients with metastatic microsatellite instability-high (MSI-H) cancers.
- To support initiation of planned Phase 3 studies, a clinical study was initiated to evaluate TSR-042 in combination with carboplatin-paclitaxel in patients with advanced or metastatic cancer.
- Enrollment continues in the Phase 1 AMBER combination study of TSR-022 (anti-TIM-3 antibody) plus TSR-042, and the Phase 1 CITRINO dose-escalation trial of TSR-033 (anti-LAG-3 antibody). Data from the monotherapy, dose-escalation portion of the AMBER trial of TSR-022 will be presented at the
Society for Immunotherapy of Cancer( SITC) annual meeting on November 10.
Third Quarter 2017 Financial Results
Net product revenue totaled
License, collaboration, and other revenue totaled
Cost of sales totaled
Research and development expenses increased to
Selling, general and administrative expenses increased to
Operating expenses as described above include total non-cash, stock-based compensation expense of
Net loss totaled
- Continue to execute on the ongoing U.S. launch of ZEJULA and solidify its position as the market-leading PARP inhibitor for patients with recurrent ovarian cancer;
- Launch ZEJULA in
Europeby year-end 2017, pending European Commissionapproval; and
- Launch VARUBI IV in the U.S.
- Rapidly advance the GARNET registration trial of TSR-042 in MSI-H cancers, with the intent of supporting accelerated
- Define the registration path in platinum-resistant ovarian cancer and triple negative breast cancer in Q1 2018, pending data from TOPACIO trial;
- Report initial data for the AMBER trial of TSR-022 in combination with TSR-042 in 2018;
- Complete the dose escalation phase of the TSR-033 CITRINO trial and in early 2018 initiate a combination trial of TSR-033 plus TSR-042;
- Initiate OVARIO, a Phase 2 clinical trial of niraparib in combination with bevacizumab in patients with first-line ovarian cancer by year end;
- Initiate a Phase 3 clinical trial of niraparib in combination with TSR-042 in first-line ovarian cancer in 1H 2018; and
- Initiate a Phase 3 clinical trial of niraparib in combination with TSR-042 in NSCLC in 2H 2018.
Today's Conference Call and Webcast
About ZEJULA (Niraparib)
ZEJULA (niraparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. In preclinical studies, ZEJULA concentrates in the tumor relative to plasma, delivering greater than 90% durable inhibition of PARP 1/2 and a persistent antitumor effect. Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML), including some fatal cases, was reported in patients treated with ZEJULA. Discontinue ZEJULA if MDS/AML is confirmed. Hematologic adverse reactions (thrombocytopenia, anemia and neutropenia), as well as cardiovascular effects (hypertension and hypertensive crisis) have been reported in patients treated with ZEJULA. Monitor complete blood counts to detect hematologic adverse reactions, as well as to detect cardiovascular disorders, during treatment. ZEJULA can cause fetal harm and females of reproductive potential should use effective contraception. Please see full prescribing information, including additional important safety information, available at www.zejula.com.
About VARUBI® (rolapitant)
VARUBI is a substance P/neurokinin-1 (NK-1) receptor antagonist indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. NK-1 receptors are highly concentrated in the brain and bind neurokinin substance P. Activation of NK-1 receptors plays a central role in nausea and vomiting induced by emetogenic stimuli, including certain cancer chemotherapies. A Positron Emission Tomography (PET) study with rolapitant in normal, healthy volunteers demonstrated that rolapitant crosses the blood brain barrier and occupies brain NK-1 receptors at high levels for up to 120 hours. VARUBI has a half-life of approximately seven days, which may contribute to the ability of a single dose of VARUBI to cover the entire delayed CINV Phase (25-120 hours). VARUBI is contraindicated in patients taking CYP2D6 substrates with a narrow therapeutic index, such as thioridazine and pimozide. VARUBI can significantly increase the plasma concentrations of thioridazine and pimozide, which may result in QT prolongation and Torsades de Pointes. VARUBI is a moderate inhibitor of CYP2D6 and significantly increases the plasma concentrations of CYP2D6 substrates for at least 28 days, with inhibitory effects expected to persist for an unknown duration. Monitor for adverse reactions when VARUBI is co-administered with CYP2D6 substrates without a narrow therapeutic index (avoid co-administration with CYP2D6 substrates with a narrow therapeutic index, thioridazine and pimozide; see Contraindication). In clinical trials, the most common adverse reactions reported were neutropenia, hiccups, decreased appetite and dizziness. IV administration of VARUBI was also associated with infusion-related symptoms (e.g., sensation of warmth, abdominal pain, dizziness, and paresthesia). Avoid use of VARUBI in patients who require chronic administration of strong CYP3A4 inducers (e.g., rifampin), as significantly reduced plasma concentrations of VARUBI can decrease the efficacy of VARUBI. Oral VARUBI is an inhibitor of breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp). Increased plasma concentrations of BCRP substrates (e.g., methotrexate, topotecan, or irinotecan) and P-gp substrates (e.g., digoxin) with a narrow therapeutic index may result in potential adverse reactions. Monitor digoxin concentrations with concomitant use of VARUBI, and adjust the dosage as needed to maintain therapeutic concentrations. Monitor INR and prothrombin time and adjust the dosage of warfarin, as needed, to maintain target INR. VARUBI is available by prescription only. Please see full prescribing information, including additional important safety information, available at www.varubirx.com.
+1.781.325.1116 or email@example.com
Associate Director, Investor Relations
+1.781.257.2505 or firstname.lastname@example.org
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding
|Unaudited Condensed Consolidated Statements of Operations|
|(in thousands, except per share amounts)|
|Three Months Ended
|Nine Months Ended
|(as revised)(1)||(as revised)(1)|
|Product revenue, net:|
|Total product revenue, net||1,326||41,755||2,844||72,723|
|License, collaboration and other revenues||15,661||101,011||50,253||102,580|
|Cost of sales - product||378||6,216||691||10,280|
|Cost of sales - intangible asset amortization||464||1,254||1,391||4,723|
|Research and development (2)||60,783||73,388||163,630||210,910|
|Selling, general and administrative (2)||37,685||83,998||104,052||246,239|
|Acquired in-process research and development||1,940||-||9,940||7,000|
|Loss from operations||(84,263||)||(22,090||)||(226,607||)||(303,849||)|
|Interest and other income (expense), net||(3,587||)||(3,048||)||(11,377||)||(9,941||)|
|Loss before income taxes||(87,850||)||(25,138||)||(237,984||)||(313,790||)|
|Provision for income taxes||-||139||-||271|
|Net loss per share applicable to|
|common stockholders - basic and diluted||$||(1.72||)||$||(0.47||)||$||(5.17||)||$||(5.82||)|
|Weighted-average number of common|
|shares used in net loss per share applicable
to common stockholders - basic and diluted
|(1) The Company adopted Financial Accounting Standards Board Accounting Standards Update No. 2014-09 effective January 1, 2017,|
|with full retrospective application to January 1, 2015. Results for periods prior to January 1, 2017 have been revised accordingly.|
|(2) Expenses include the following amounts of non-cash stock-based compensation expense:|
|Research and development||$||5,605||$||8,545||$||13,826||$||23,532|
|Selling, general and administrative||7,314||16,471||20,238||43,393|
|Unaudited Condensed Consolidated Balance Sheets|
|Cash and cash equivalents||$||785,877||$||521,265|
|Other current assets||10,515||22,257|
|Total current assets||817,287||621,729|
|Intangible assets, net||12,877||43,155|
|Property and equipment, net||6,640||9,877|
|Liabilities and stockholders' equity|
|Deferred revenue, current||95||95|
|Other current liabilities||2,978||2,287|
|Total current liabilities||77,009||131,442|
|Convertible notes, net||131,775||140,362|
|Deferred revenue, non-current||305||235|
|Other non-current liabilities||5,086||6,318|
|Total stockholders' equity||628,118||407,361|
|Total liabilities and stockholders' equity||$||842,293||$||685,718|
|(1) The Company adopted Financial Accounting Standards Board Accounting Standards|
|Update No. 2014-09 effective January 1, 2017, with full retrospective application to January 1,|
|2015. Results for periods prior to January 1, 2017 have been revised accordingly.|
Source: TESARO, Inc.